News | May 02, 2014

Late-Breaking Trials to be Presented at SCAI Announced

Late-Breaking Trials SCAI May 2014

May 2, 2014 — The Society for Cardiovascular Angiography and Interventions (SCAI) announced the late-breaking clinic al trial data presentations for it its upcoming 2014 Scientific Sessions, May 28-31, in Las Vegas. The late-breaking clinical trials will be presented Friday, May 30, from 2-3 p.m. PST. These are:

• Effect of a Real Time Radiation Monitoring Device on Radiation Exposure During Cardiac Catheterization: The Radiation Reduction during Cardiac Catheterization Using Real Time Monitoring (RadiCure) Study, presented by Georgios Christopoulos, M.D.

• Diamondback 360° Coronary Orbital Atherectomy System for Treating De Novo, Severely Calcified Lesions: ORBIT II 1-Year Results and Cost Comparison to a Sample of Medicare Hospital Claims, presented by Jeffrey Chambers, M.D., FSCAI

• Comparison of Lesion Level Decision Making in the Cath Lab Using Hyperemic and Non-Hyperemic Pressure Wire Derived Indices of Stenosis Severity: The VERIFY-2 Study, presented by Stuart Watkins, M.D.

• 3-Dimensional Quantitative Coronary Angiography Using Coronary Catheters as Objective Markers Reliably Unmasks Severe Occult Stenosis in Diffusely Diseased Vessels: New Results from the IQ-CATEGORIZE Lesions Study, presented by Charles Laham, M.D., FSCAI

This year’s keynote speakers will discuss hot topics in interventional cardiology, including the challenges and opportunities today’s professionals face:

• Martin Leon, M.D., FSCAI, will focus on the evolution of innovation in interventional cardiology. Leon’s remarks will touch on the past and present of the field, but will emphasize the future of one of the most rapidly evolving, cutting-edge areas of medicine and the role of each professional in continuing to break new ground in ever-improving patient care.

• Pediatric interventional cardiologist James E. Lock, M.D., will address the obstacles involved in development of new and effective treatments for the littlest hearts, including clinical trial execution. Lock will discuss his step-by-step process for successful innovation amidst these challenges and will challenge the interventional cardiology community to innovate, offering kids the best chance to grow and thrive.  

• Patrick T. O’Gara, M.D., will explore the dynamic challenges facing the cardiovascular workforce, including restrictions to Medicare-based funding for residencies and the growing gap between the demand for cardiovascular specialists and the supply. O’Gara also will present practical solutions for interventional cardiologists and their practices to implement as the healthcare environment continues to evolve.

For more information: www.scai.org/SCAI2014


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now